OptiNose

OptiNose — Investor Presentation (November 2017)

24 slides from OptiNose's investor presentation, Nov 15, 2017

  1. Slide 1: Building a Leading Specialty Biopharma Company in ENT / Allergy

    Building a Leading Specialty Biopharma Company in ENT / Allergy Company Presentat ion 1 5 N o v e m b e r 2 0 1 7

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Emerging Growth Company with Approved Products

    3 Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY • 3.5 million CRS patients (1.2M with nasal polyps) being treated by 15,000 physicians • Limited competition anticipated from any pharma companies at launch XHANCE Represents a Significant Opportunity

  4. Slide 4: Attractive Market Opportunity in Chronic Rhinosinusitis (CRS)

    4 Attractive Market Opportunity in Chronic Rhinosinusitis (CRS) Potential to Become Part of the Standard of Care Potential Favorable Market Access due to Pricing Strategy & Pharmacoeconomics Concentrated Target Market Activated Through Specialty Sales Force Patent Portfolio and Regulatory Barriers S

  5. Slide 5: Experienced Leadership Team

    5 Experienced Leadership Team Peter Miller Chief Executive Officer and Director Ramy Mahmoud, MD, MPH, FACP President & Chief Operating Officer Tom Gibbs Chief Commercial Officer Keith Goldan Chief Financial Officer

  6. Slide 6: Large CRS Population with Severe Symptoms

    6 Mild Moderate Severe • Highly prevalent in the United States (~65M) • Largely OTC / generic market • Well-treated using INS Allergic Rhinitis * Based on US Adult Population Survey (n=10,336). • ~30M US adults suffer from CRS—up to 10M with Nasal Polyps • 9.75M patients actively seeking physician c

  7. Slide 7: CRS with or without Polyps: The Root Issue Is Inflammation

    7 • A diagnosis characterized by chronic inflammation • Persistent inflammation causes pain and obstruction deep in the nasal passages and openings to the sinuses • Primary defining symptoms include congestion, facial pain/pressure, rhinorrhea and loss of smell/taste • Acute flares are frequent comp

  8. Slide 8: CRS Patients Suffer High Disease Burden

    8 CRS Patients Suffer High Disease Burden Source: Naïve patient survey, Physician survey. Patients Frequently Endure Severe Symptoms Throughout the Year • Disease persists for many years • Significant Quality of life impact (comparable to CHF, COPD, Angina) Additional Symptoms are Common and can be

  9. Slide 9: Existing Treatments are Sub-Optimal

    9 High Cost, Typically Not Curative Sinus Surgery ~80% of patients continue to have symptoms after surgery Continuing Nasal Steroid use after surgery is typical $8,500–$16,000 per procedure, and repeat surgery is not uncommon Limited Efficacy Medical Management Saline nasal spray, irrigations, neti

  10. Slide 10: Problem and Solution: Exhalation Delivery System (EDS)

    10 Problem: Nasal sprays and aerosols do not effectively place drug high and deep in the nasal passages Solution: Unique new concept for delivery gets medicine where it needs to be to work Drug released into airflow Pressure balances Soft palate closes Blow into device Press bottle up to open device

  11. Slide 11: Optinose EDS Delivers Drug High and Deep in the Nose

    11 Optinose EDS Traditional Spray Intranasal steroids are well-tolerated TOPICAL TREATMENTS and only work where they are delivered Tight spaces in the region where sinuses normally open and drain Optinose EDS Delivers Drug High and Deep in the Nose KEY TO TREATING CS (with or without polyps) IS REAC

  12. Slide 12: Global Clinical Program

    12 Trial Type N Sites NAVIGATE I Phase 3 pivotal 323 54 NAVIGATE II Phase 3 Pivotal 323 38 EXHANCE-3 Phase 3 open-label 3 month 700 38 EXHANCE-12 Phase 3 open-label 12 month 223 21 Study 1102 Phase 1 bioavailability 112 2 Global Clinical Program Significant benefit on all four defining symptoms of C

  13. Slide 13: Potential to Become Part of Standard of Care

    13 * Not currently in guidelines. ^ Currently marketed for other indications and in development for nasal polyps indication. Potential to Become Part of Standard of Care ADAPTED FROM INTERNATIONAL CONSENSUS STATEMENT ON ALLERGY AND RHINOLOGY (ICAR) * After Failure of Current Medical Management INVAS

  14. Slide 14: Commercialization Strategy to Build XHANCE into a Leading Product

    14 WAVE 1 Enter High-Density ENT/Allergy Specialty Market • 15,000 Physician Targets • Ramping up to 150 Sales Reps • Limited Competition • Promotion of Nasal Polyp Indication ~3.5M Patients (1.2M with Nasal Polyps) WAVE 2 Facilitate Broader Adoption in Primary Care • Future Chronic Sinusitis indica

  15. Slide 15: 30M US Adults Suffer from Chronic Rhinosinusitis

    15 96.1% 0 5 10 15 20 25 30 35 40 45 Database Population % of Population with no CRS Claim % of Population with CRS Claim P at ie n t Cla im s Da ta b as e 41M 3.9% 30M US Adults Suffer from Chronic Rhinosinusitis ~9.75M PATIENTS CURRENTLY UNDER ACTIVE CARE OF A PHYSICIAN FOR CRS Approximately 3.9%

  16. Slide 16: Pricing Landscape Offers Attractive Scenarios

    16 * BID dosing required for the treatment of nasal polyps, based upon Nasonex data and academic literature. WAC prices reflect a 2x multiple on the WAC price for conventional INS due to the approved dose for the treatment of nasal polyps. ^ Nasonex and Mometasone are currently the only other intran

  17. Slide 17: Total Market Opportunity of >$9.5B

    17 PREVALENCE OVERALL TREATED PATIENTS TREATED PATIENTS IN SEGMENT TOTAL ANNUAL US MARKET OPPORTUNITY SEGMENT ANNUAL MARKET OPPORTUNITY INCREMENTAL PCP OPPORTUNITY (1) Target market represents ~10,000 ENT and allergy specialists and ~5,000 high-decile INS prescribing primary care physicians. (2) Bas

  18. Slide 18: Differentiated Physician Reaction to Profile

    18 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Allergists ENTs PCPs Lik el ih o o d t o Pr es cr ib e N=200 N=202 N=302 Percent of HCPs stating they will “definitely” or “probably” prescribe XHANCE Differentiated Physician Reaction to Profile SUGGESTS HIGH LAUNCH INTEREST AND STANDARD OF CARE POTENTIAL P

  19. Slide 19: Favorable Pharmacoeconomic Profile Offers Promising Market Access Dynamics

    19 Favorable Pharmacoeconomic Profile Offers Promising Market Access Dynamics RESEARCH* INCLUDING 25 PAYORS REPRESENTING OVER 150M LIVES PRODUCT Payors grasp the underlying science/technology of XHANCE PRICE Need to Price “reasonably” CONTROL Payors “do not” / “do not want” to manage actively MARKET

  20. Slide 20: Efficient, Specialty-Focused, Go-to-Market Commercialization Model

    20 Efficient, Specialty-Focused, Go-to-Market Commercialization Model to Launch XHANCE XHANCE Territories (assuming full deployment) Approximately 75 designated territory managers at launch growing to 150 based on expansion of market access Specialties: ENT, allergists and high-decile, INS-prescribi

  21. Slide 21: Multi-Channel Approach to Drive Rapid Trial and Adoption

    21 Multi-Channel Approach to Drive Rapid Trial and Adoption Pre-PDUFA Post Approval/Pre-Launch Launch Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep DIGITAL, SOCIAL AND NPP CLINICAL NURSE EDUCATORS OPTINOSE SALES FORCE 75 Sales Representatives Deployed Based Upon Access Planning for ~20

  22. Slide 22: Optinose EDS Finally Enables Delivery of Drug to Target Sites

    22 Optinose EDS Finally Enables Delivery of Drug to Target Sites High/Deep in the Nose: Differentiated Clinical Profile Brand Differentiation Unmet Need • Patients and physicians cite limited efficacy as the most important unmet need for treating CS with or without Nasal Polyps Unsatisfied / engaged

  23. Slide 23: PBM Access Planning Scorecard

    23 PBM Access Planning Scorecard PBM Q3 2017 Q4 2017 through Q1 2018 Lives: 28.0M Lives: 36.0M Lives: 11.0M Lives: 1.0M Lives: 9.0M Task Completed Complete introductory presentation Complete clinical presentation Submit term sheet Potential formulary approval Key

  24. Slide 24: Attractive Market Opportunity in Chronic Rhinosinusitis (CRS)

    24 Attractive Market Opportunity in Chronic Rhinosinusitis (CRS) Potential to Become Part of the Standard of Care Potential Favorable Market Access due to Pricing Strategy & Pharmacoeconomics Concentrated Target Market Activated Through Specialty Sales Force Patent Portfolio and Regulatory Barriers

OptiNose — Investor Presentation (November 2017) on 6ix